Sophie Matheron

ORCID: 0000-0001-7879-6553
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • HIV-related health complications and treatments
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Cytomegalovirus and herpesvirus research
  • HIV, Drug Use, Sexual Risk
  • Hepatitis C virus research
  • Malaria Research and Control
  • Mosquito-borne diseases and control
  • Hepatitis B Virus Studies
  • Parasites and Host Interactions
  • Travel-related health issues
  • Viral-associated cancers and disorders
  • Immune Cell Function and Interaction
  • Antibiotic Resistance in Bacteria
  • Healthcare Systems and Practices
  • Parasitic Infections and Diagnostics
  • Tuberculosis Research and Epidemiology
  • Herpesvirus Infections and Treatments
  • T-cell and Retrovirus Studies
  • Mycobacterium research and diagnosis
  • Enterobacteriaceae and Cronobacter Research
  • Ocular Diseases and Behçet’s Syndrome
  • Pneumonia and Respiratory Infections

Université Claude Bernard Lyon 1
2015-2024

Sorbonne Paris Cité
2012-2024

Hôpital Bichat-Claude-Bernard
2015-2024

Assistance Publique – Hôpitaux de Paris
2015-2024

Délégation Paris 7
2014-2024

Université Paris Cité
2015-2024

Centre de recherche en Epidémiologie et Santé des Populations
2014-2024

Inserm
2015-2024

Hôpitaux Universitaires Paris-Ouest
2023-2024

Bordeaux Population Health
2020-2024

Laurent Mandelbrot Roland Tubiana Jérôme Le Chenadec Catherine Dollfus Albert Faye and 95 more E. Pannier Sophie Matheron Marie-Aude Khuong Valérie Garrait Véronique Reliquet Alain Devidas Alain Berrébi C Allisy Christophe Elleau C. Arvieux Christine Rouzioux Josiane Warszawski Stéphane Blanche Laurent Mandelbrot C. Crenn-Hébert Corinne Floch-Tudal Fabienne Mazy Marine Joras Françoise Meier Emmanuel Mortier Pierre‐François Ceccaldi Maïa Banigé Agnès Uludag Virginie Zarouk A. Lefort Gilles Hittinger Jean-Marc Chamouilli Christian Burle Alain Lafeuillade Marie Medus Germaine Bachelard Joëlle Dendale-Nguyen Thomas Guimard Karine Guimard Jean-Pierre Brossier Philippe Van de Perre Jean-Luc Esnault Olivier Bollengier Stragier Sophie Leautez-Nainville Sandrine-Anne Martha Benoît Martha E. Maurel Michel Françoise Muriel Barat Patricia Murger Mahfoud Rouha P Lumbroso A Checoury Pascale Perfezou Gilles Blondin Séverine Ansart Luc de Saint Martin Philippe Le Moine Corinne Daniel Christian Calvez Emmanuelle Boutard C. Arvieux Estelle Bauville Christelle Dupre Yves Poinsignon Anne Grelier Gaétane Mousset Corinne Cudeville Mathilde Niault Isabelle Belzic Philippe Moreau Marie-Françoise Le Coz Odile Luycx Vaillant Virginie Vitrat D. Tardif Jacques Gaillat Anne Vanderbergh Suzanne Braig Marion Dehlinger-Paul Khaled Mohamed Brigitte Heller-Roussin Cécile Winter Ghislaine Firtion E. Pannier Myriam Costa Odile Launay Dominique Salmon Ceron Sophie Matheron Mandovi Rajguru Neila Elaoun Lahcene Allal Élie Azria Agnès Bourgeois Moine Valérie Garrait Isabelle Hau Claudine Touboul Lanto Ratsimbazafy Christiane Kommé Brigitte Elharrar Jean-Marc Labaune

Abstract Background. The efficacy of preventing perinatal transmission (PT) human immunodeficiency virus type 1 (HIV-1) depends on both viral load (VL) and treatment duration. objective this study was to determine whether initiating highly active antiretroviral therapy (ART) before conception has the potential eliminate PT. Methods. A total 8075 HIV-infected mother/infant pairs included from 2000 2011 in national prospective multicenter French Perinatal Cohort (ANRS-EPF) received ART,...

10.1093/cid/civ578 article EN Clinical Infectious Diseases 2015-07-21

In this study we analyzed the influence of human immunodeficiency virus (HIV) infection on course chronic hepatitis C through multivariate analysis including age, alcohol consumption, immune status, and (HCV)-related virologic factors. Eighty HIV-positive 80 HIV-negative injection drug users included between 1980 1995 were matched according to gender, duration HCV followed-up during 52 months. The progression cirrhosis was primary outcome measure. impact HIV HCV-RNA load, histologic activity...

10.1053/jhep.2001.29201 article EN Hepatology 2001-12-01

Objective To assess the respective value of phenotype versus genotype standard care for choosing antiretroviral therapy in patients failing protease inhibitor-containing regimens. Methods Patients with plasma HIV-1 RNA exceeding 1000 copies/ml were randomly allocated to phenotyping, genotyping, or care. Results Five-hundred and forty-one randomized, 190 192 genotyping 159 The baseline median CD4 cell count (280 × 106cells/l), level (4.3 log10 copies/ml), number drugs previously received (n =...

10.1097/00002030-200203290-00008 article EN AIDS 2002-03-01

We report the complete genome sequence of a highly divergent strain human immunodeficiency virus type 2 (HIV-2), 96FR12034, identified in France from patient West African origin. This lineage, H, represents only third definitive instance monkey-to-human transfer SIVsm that has given rise to pathogenic HIV-2. As different "subtypes" HIV-2 are analogous groups HIV-1 we propose subtypes henceforth by renamed agreement with HIV Nomenclature Committee. The single-strain lineages C G and 96FR12034...

10.1089/0889222041217392 article EN AIDS Research and Human Retroviruses 2004-06-01

Objective To determine circulating viral load in HIV-2-infected individuals. Methods Viral was determined 40 adults using standardized quantitative cell and qualitative plasma viraemia assays. We also tested for proviral HIV-2 DNA single nested polymerase chain reaction (PCR) fresh lymphocytes from 27 subjects. The results were compared, on the basis of CD4+ lymphocyte count, with our published data HIV-1 infection. Results isolated peripheral blood mononuclear cells (PBMC) 19 individuals...

10.1097/00002030-199311000-00002 article EN AIDS 1993-11-01
Nelly Briand Josiane Warszawski Laurent Mandelbrot Catherine Dollfus E. Pannier and 95 more L. Cravello Rose Nguyen Sophie Matheron Norbert Winer Roland Tubiana Christine Rouzioux Albert Faye Stéphane Blanche Laurent Mandelbrot Françoise Meier Dominique Duro Marine Joras E. Mortier C. Crenn-Hébert Corinne Floch-Tudal Fabienne Mazy M. Bensalah Agnès Villemant-Uludag A. Lefort Virginie Zarrouk Pierre‐François Ceccaldi Gisèle Philip Gilles Hittinger Martine Malet B. Bachelard Marie Medus Joëlle Dendale-Nguyen Jean-Pierre Brossier Olivier Aubry Jean-Luc Esnault S Léautez Philippe Van de Perre Isabelle Suaud Sandrine-Anne Martha Mahfoud Rouha Pascale Perfezou G Blondin Charles Bellot Séverine Ansart Philippe Le Moine Karine Bages-Jaffuel Jean-Charles Duthé M. Garrè S. Jaffuel Corinne Daniel Christian Calvez C. Beuscart Emmanuelle Boutaric Jennifer Rohan Sylvie Lemoal L. Lassel Ghislaine Cotten Caroline Dupré Esther Beauville C. Arvieux Anabèle Dos Santos Corinne Cudeville Yves Poinsignon Virginie Mouton-Rioux Gaétane Mousset Anne Grellier Philippe Moreau Philippe Tillaut Virginie Mouton-Rioux Odile Luycx-Vaillant Philippe De Morel Marie-Françoise Le Coz Isabelle Belzic M. Niault Anne Vandenbergh C. Janssen Suzanne Braig Virginie Vitrat J. Gaillat Gaëlle Clavere J.P. Bru Blandine Peyret Catherine Mullard Marie Echard Philippe Talon Marjorie Dehlinger Cécile Winter Brigitte Heller-Roussin Odile Launay M Fouchet Ghislaine Firtion Isabelle Goupil E. Pannier Nora Boudjoudi Agnès Bourgeois-Moine M Bodard Valérie Vivier Mandovi Rajguru Virginie Huri Élie Azria

Intrapartum intravenous zidovudine (ZDV) prophylaxis is a long-standing component of prevention mother-to-child transmission (MTCT) human immunodeficiency virus (HIV) in high-resource countries. In some recent guidelines, ZDV no longer systematically recommended for mothers receiving combination antiretroviral therapy (cART) with low viral load. We evaluated the impact according to load and obstetrical conditions. All HIV-1-infected women delivering between 1 January 1997 31 December 2010...

10.1093/cid/cit374 article EN Clinical Infectious Diseases 2013-05-31

We investigated the in vitro phenotypic susceptibility of HIV-2 isolates from integrase inhibitor (INI)-naive patients to INIs and its relation gene polymorphism.We determined raltegravir elvitegravir co-cultured obtained ROD reference strain 14 clinical isolates. IC(50) values were compared with those for HIV-1 strains. polymorphism was assessed 52 INI-naive enrolled French cohort.Median 2.4 0.7 nM, respectively, similar observed Overall, 38% amino acids polymorphic. The catalytic triad DDE...

10.1093/jac/dkn335 article EN Journal of Antimicrobial Chemotherapy 2008-07-18

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, darunavir are potent against wild-type HIV-2 should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors less active than HIV-1.

10.1128/aac.01284-07 article EN Antimicrobial Agents and Chemotherapy 2008-01-29

The first reports on the pandemic influenza 2009 A/H1N1v from USA, Mexico, and Australia indicated that this disease was associated with a high mortality in pregnant women. aim of study to describe compare characteristics severe critically ill non-severe women A/H1N1v-related illness France.A national registry created screen laboratory-confirmed influenza. Three hundred fifteen patients 46 French hospitals were included: 40 admitted intensive care units (severe outcomes), 111 hospitalized...

10.1371/journal.pone.0013112 article EN cc-by PLoS ONE 2010-10-05

The French Hospital Database on HIV (FHDH) is a hospital-based multicentre open cohort with inclusions ongoing since 1989. research objectives focus mainly mid- and long-term clinical outcomes therapeutic strategies, as well severe AIDS non-AIDS morbidities, public health issues relative to infection. FHDH also serves describe HIV-infected patients receiving hospital care in France. includes data more than 120 000 from 70 general or university hospitals distributed throughout Patients are...

10.1093/ije/dyu002 article EN International Journal of Epidemiology 2014-02-17
Clément Taron-Brocard Jérôme Le Chenadec Albert Faye Catherine Dollfus Tessa Goetghebuer and 95 more Vincent Gajdos Jean-Marc Labaune Anaïs Perilhou Laurent Mandelbrot Stéphane Blanche Josiane Warszawski Laurent Mandelbrot C. Crenn-Hébert Corinne Floch-Tudal Fabienne Mazy Marine Joras Françoise Meier E. Mortier Pierre‐François Ceccaldi Maïa Banigé Agnès Uludag Virginie Zarouk A. Lefort Gilles Hittinger J.-M. Chamouilli Christian Burle Alain Lafeuillade M. Médus Gastón Bachelard Joëlle Dendale-Nguyen Thomas Guimard Karine Guimard Jacques Brossier Philippe Van de Perre J.-L. Esnault Olivier Bollengier Stragier Sophie Leautez-Nainville Sandrine Anne Martha B. Martha E. Maurel M Françoise M. Barat Patricia Murger Mahfoud Rouha P Lumbroso A Checoury Pascale Perfezou G Blondin Séverine Ansart Luc de Saint Martin Philippe Le Moine C Daniel Christian Calvez Emmanuelle Boutard C. Arvieux Estelle Bauville Caroline Dupré Yves Poinsignon Aurore Grelier Gaétane Mousset Corinne Cudeville M. Niault Isabelle Belzic Philippe Moreau Marie Francoise Le Coz O. Vaillant Virginie Vitrat D. Tardif J. Gaillat Anne Vanderbergh Suzanne Braig M. Dehlinger-Paul Kamal A. Mohamed Brigitte Heller-Roussin Cécile Winter Ghislaine Firtion E. Pannier Maria Laura Costa Odile Launay Dominique Salmon Ceron Sophie Matheron M. Rajguru Neila Elaoun Lahcene Allal Élie Azria Agnès Bourgeois Moine Valérie Garrait Isabelle Hau Cyril Touboul Lanto Ratsimbazafy Christiane Kommé Brigitte Elharrar Jean-Marc Labaune Laurent Cotte R.-C. Rudigoz Christophe Elleau C. Runel-Belliard T. Pistone Blandine Muanza E. Broustal

Background. Morbidity and mortality are higher among human immunodeficiency virus (HIV) exposed but uninfected (HEU) infants than unexposed infants, particularly if the mother had a low CD4 count. We investigated possible association between maternal immune depression during pregnancy risk of infection in HEU national French Perinatal Cohort (EPF). Methods. All neonates, born alive, to HIV-1–infected women enrolled EPF 2002 2010 were included. The primary outcome was first serious...

10.1093/cid/ciu586 article EN Clinical Infectious Diseases 2014-07-22

Healthy travellers to countries where carbapenemases-producing Enterobacteriaceae (CPE) are endemic might be at risk for their acquisition, even without contact with the local healthcare system. Here, we report acquisition of CPE (two OXA-181, one New Delhi metallo-beta-lactamase 1 (NDM-1)) in three healthy returning from India. The duration intestinal carriage was less than month. results indicate that recently India considered as carriage.

10.2807/1560-7917.es2014.19.14.20768 article EN cc-by Eurosurveillance 2014-04-10
Coming Soon ...